In re Generic Pharm. Pricing Antitrust Litig.
368 F. Supp. 3d 814
E.D. Pa.2019Background
- This multidistrict litigation alleges a nationwide conspiracy by generic drug manufacturers to fix prices, allocate markets, and rig bids for six "Group 1" drugs (clobetasol, digoxin, divalproex ER, doxycycline, econazole, pravastatin).
- End-Payer Plaintiffs (EPPs) (health plans, unions, insurers, individuals) and Indirect-Reseller Plaintiffs (IRPs) (independent pharmacies) bring state-law antitrust, consumer-protection, and unjust-enrichment claims as indirect purchasers barred from federal antitrust damages by Illinois Brick.
- Plaintiffs asserted claims under the laws of many states/territories (classwide), though named plaintiffs did not allege purchases or residency in every jurisdiction where claims were pleaded.
- Defendants moved to dismiss (Rule 12(b)(1) & (6)): arguing lack of Article III standing for out-of-state claims, state-law pleading deficiencies (nexus/intrastate conduct, consumer/consumer-definition, pre-suit notice, class-action bars), unjust-enrichment limits, and statute-of-limitations defenses.
- The court reserved on state-law claims after adjudicating federal Sherman Act claims, and here rules: it largely refuses to dismiss class-state claims for lack of Article III standing, but dismisses certain state-specific claims with prejudice (notably Illinois Antitrust Act claims and specified consumer-protection exclusions).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Article III standing to assert state-law claims on behalf of absent class members | Named EPPs/IRPs have a shared, concrete interest in proving a nationwide overcharge scheme; class standing should be resolved at Rule 23 stage | Named plaintiffs lack Article III standing to assert claims under laws of states where they did not reside or purchase | Court: Denied dismissal on standing grounds. So long as named reps have personal standing, classwide state-law claims are evaluated at class-certification (Rule 23) rather than dismissed for lack of Article III standing |
| Whether state antitrust and consumer-protection claims must be dismissed for failure to plead intrastate nexus or other state-specific elements | Nationwide scheme allegations plus allegations of purchases at supracompetitive prices within states suffice to plead intrastate effect and elements | Many state claims lack particularized in-state conduct, residency, or statutory prerequisites; some consumer statutes do not cover antitrust-type conduct or indirect purchasers | Court: Nationwide-scheme allegations were sufficient at pleading stage for most state antitrust and consumer claims; specific state challenges generally denied, subject to later factual development |
| Effect of Illinois Antitrust Act and other state class-action bars (and Shady Grove) on class claims | Plaintiffs: federal Rule 23 governs class actions in federal court; state bars are procedural and should not defeat class certification here | Defendants: Illinois statute (and some state consumer statutes) substantively bar indirect-purchaser class actions; state policy should control under Shady Grove/Erie | Court: Illinois Antitrust Act class-action bar is substantive and defeats indirect-purchaser class claims under Illinois law — those claims dismissed with prejudice; also dismissed class claims under Montana and South Carolina consumer-protection statutes (court found their class-action bars substantive). Other state bar/contentions largely rejected or deferred to Rule 23 analysis |
| Viability of unjust-enrichment claims given Illinois Brick and direct-benefit requirements | Plaintiffs: Illinois Brick does not extinguish common-law equitable claims; unjust-enrichment focuses on defendants' gains and plaintiffs plausibly allege they conferred non-incidental benefit (overpayments) | Defendants: Illinois Brick bars indirect-recovery remedies; unjust-enrichment requires direct conferment of benefit or lack of adequate legal remedy | Court: Illinois Brick does not automatically bar unjust-enrichment claims; plaintiffs plausibly alleged that benefits flowed to defendants and that alternative remedies may be inadequate — unjust-enrichment claims survive pleading-stage challenges |
Key Cases Cited
- Illinois Brick Co. v. Illinois, 431 U.S. 720 (states that indirect purchasers cannot recover treble damages under federal antitrust law)
- Lujan v. Defenders of Wildlife, 504 U.S. 555 (standing requirements: injury-in-fact, causation, redressability)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (pleading standard for antitrust conspiracies; plausibility requirement)
- Neale v. Volvo Cars of N. Am., LLC, 794 F.3d 353 (3d Cir. 2015) (named plaintiff standing suffices to sustain class action case-or-controversy under Article III)
- Shady Grove Orthopedic Ass'n v. Allstate Ins. Co., 559 U.S. 393 (federal procedural rules may be displaced where state rule is part of state's substantive framework)
- In re Lipitor Antitrust Litig., 868 F.3d 231 (3d Cir.) (discussion of interplay between Rule 23 and state statutes barring indirect-purchaser class actions)
- In re Generic Pharm. Pricing Antitrust Litig., 338 F. Supp. 3d 404 (E.D. Pa. 2018) (earlier MDL opinion resolving federal Sherman Act claims and reserving state-law issues)